DIABETES MELLITUS

Hitler Mateus M
Departemento De Farmácia
 Definisaun
- OMS : DM defini nudar doença ida ou distúrbio metabó
lico crônica ho multi etiologia nebe ho caracteriza níveis
açúcar acompanhados ho distúrbios do metabolismo de
carboidratos, lipídios no proteínas tanba insuficiência
função husi insulina.

- DM :mak grupo ida husi distúrbios metabólicos nebe ca

racterizados ho hiperglicemia no anormalidades iha me
tabolismo carboidratos,gorduras no proteínas. doença ida
ne tamba defisiénsia iha sekresaun insulina, sensibilidade
insulina, ka ambos.Komplikasaun krónika mikrovaskular,
makrovaskular no neuropatiku bele mosu.
01
ABSTRACT
FISIOPATOLOGIA

PATIENT CLINICAL DIAGNOSTIC

PROFILE FINDINGS WORKUP
Include essential Present an overview of Outline the diagnostic
demographic the patient's physical process, including the
information such as age, examination findings, reasoning behind the
gender, and medical laboratory test results chosen investigations
history. Describe the and any imaging or and tests. Discuss the
patient's chief diagnostic procedures. results, their
complaint and the Highlight key interpretation and their
timeline of symptoms abnormalities that aid in contribution to reaching
leading to the diagnosis the diagnosis the final diagnosis
FISIOPATOLOGIA

PATIENT CLINICAL DIAGNOSTIC

PROFILE FINDINGS WORKUP
Include essential Present an overview of Outline the diagnostic
demographic the patient's physical process, including the
information such as age, examination findings, reasoning behind the
gender, and medical laboratory test results chosen investigations
history. Describe the and any imaging or and tests. Discuss the
patient's chief diagnostic procedures. results, their
complaint and the Highlight key interpretation and their
timeline of symptoms abnormalities that aid in contribution to reaching
leading to the diagnosis the diagnosis the final diagnosis
APRESENTAÇÃO CLÍNICA
Perda de
01 Polyuria 04 peso

Letargia
Polydipsia
02 05 ( murón )

Polyphagia
03
MILESTONES REACHED
Initial presentation Monitoring response
with chief complaint for treatment

Diagnostic evaluation Resolution of

and investigations presenting symptoms

Confirmation of Follow-up assessment

the diagnosis for outcomes

Initiation of Case discussion and

appropriate treatment lessons learned
RESULTADO DESEJADO

Os objetivos ba terapia DM :
- melhorar sintomas husi hiper
glicemia
- reduzir mosu no progressão
complicações microvasculares
no macrovasculares
- reduzir a mortalidade
- melhorar qualidade de vida
TRATAMENTO
PATIENTS AGE GENDER M. HISTORY SYMPTOMS DIAGNOSIS

PATIENT 1 45 Male Hypertension Symptom Diagnosis 1

PATIENT 2 32 Female Asthma Symptom Diagnosis 2

PATIENT 3 60 Male Diabetes Symptom Diagnosis 3

PATIENT 4 50 Female None Symptom Diagnosis 4

PATIENT 5 28 Male None Symptom Diagnosis 5

PATIENT 6 70 Female Osteoarthritis Symptom Diagnosis 6

INSULINA
PATIENTS AGE GENDER M. HISTORY SYMPTOMS DIAGNOSIS

PATIENT 1 45 Male Hypertension Symptom Diagnosis 1

PATIENT 2 32 Female Asthma Symptom Diagnosis 2

PATIENT 3 60 Male Diabetes Symptom Diagnosis 3

PATIENT 4 50 Female None Symptom Diagnosis 4

PATIENT 5 28 Male None Symptom Diagnosis 5

PATIENT 6 70 Female Osteoarthritis Symptom Diagnosis 6

INSULINA
PATIENTS AGE GENDER M. HISTORY SYMPTOMS DIAGNOSIS

PATIENT 1 45 Male Hypertension Symptom Diagnosis 1

PATIENT 2 32 Female Asthma Symptom Diagnosis 2

PATIENT 3 60 Male Diabetes Symptom Diagnosis 3

PATIENT 4 50 Female None Symptom Diagnosis 4

PATIENT 5 28 Male None Symptom Diagnosis 5

PATIENT 6 70 Female Osteoarthritis Symptom Diagnosis 6

INSULINA
INSULINA
- Dose insulin ba DM tipo I : 0,5 – 0,6 unit / kg peso
- Dose insulina ba DM tipo I fase lua da mel : 0,1 – 0,4 unit/kg
peso
- Dose insulina DM tipo II : 0,7 – 0,25 unit /kg peso
- Efeito kolateral nebe mais comum husi utiliza insulina mak
Hipoglikemia.
- Tratamentu ba Hipoglikemia:
1. Glicose (10 a 15 g) administrada por via oral mak
tratamento recomendado em pacientes
conscientes
2. Dextrose IV necessária iha indivíduos nebe lakon
consciência
3. Glukagona, 1 g IM, mak tratamentu atu hili pasiente
sira ne’ebé la iha konxiensia bainhira labele estabe
lese asesu ba IV.
A PICTURE
IS WORTH A
THOUSAND
WORDS
Using an image in your case
report enhances visual
representation and provides a
concise and impactful way to
present key findings or illustrate
important aspects of the case
SULFONILUREAS

- Conheçe iha gerasaun 2

1.gerasaun primeiro
Tolbutamid,Tolazamid,Asetoheksimid,Klorpropa
mid
2. gerasaun Segundo : Gliburid ( Glibenklamid ),
Glipizid,Gliklazid, Glimepirid
-Mekanismo serviço : estimula sekresaun insulina
iha pancreas.
- efeito kolateral : Hipoglikemik
SULFONILUREAS

- Conheçe iha gerasaun 2

1.gerasaun primeiro
Tolbutamid,Tolazamid,Asetoheksimid,Klorpropa
mid
2. gerasaun Segundo : Gliburid ( Glibenklamid ),
Glipizid,Gliklazid, Glimepirid
-Mekanismo serviço : estimula sekresaun insulina
iha pancreas.
- efeito kolateral : Hipoglikemik
CONTENTS OF THIS TEMPLATE
You can delete this slide when you’re done editing the presentation

Fonts To view this template correctly in PowerPoint, download and install the fonts we used

Used and alternative resources An assortment of graphic resources that are suitable for use in this presentation

Thanks slide You must keep it so that proper credits for our design are given

Colors All the colors used in this presentation

Icons and infographic resources These can be used in the template, and their size and color can be edited

Editable presentation theme You can edit the master slides easily. For more info, click here

For more info: You can visit our sister projects:

SLIDESGO | BLOG | FAQs FREEPIK | FLATICON | STORYSET | WEPIK | VIDEVO
Secretagogos de insulina de ação curta (meglitinidas)

-mekanismo serviço hanesan grupo

Sulfonilurea, maibe strukturaquimica la
hanesan
- risco hipoglicêmico parece ser menor com
meglitinidas do que comsulfonilureia
- exemplo medikamento grupo Meglitinidas
mak :
1. Repaglinid : 3 x 0,5 – 2 mg pc
2. Nateglinid : 3 x 120 mg p.c
Secretagogos de insulina de ação curta (meglitinidas)

DIFFERENTIAL DIAGNOSIS TREATMENT

Explore potential diagnoses based on the Present the confirmed diagnosis and
patient's presentation and relevant explain diagnostic criteria. Outline the
findings. Discuss distinguishing features chosen treatment approach and
for each and reasons for rationale behind it
inclusion/exclusion

CLINICAL COURSE LESSON LEARNED

Describe the patient's progression, Discuss the case's educational value,
treatment response and any significant highlighting unique aspects. Share
events or complications. Summarize the insights gained, including diagnostic
final outcome challenges, treatment considerations or
disease mechanisms
Biguanidas

- mekanismo serviço :Aumenta a sensibilidade

à insulina dos tecidos hepáticos e perifé
ricos (musculares).
- exemplo medikamento :
- Metformin : 500 mg x 2 – 3 p.c
Tiazolidinedionas (Glitazonas )

- mekanismo serviço : aumenta sensibilidade

insulina
- exemplo medikamento
1. Rosiglitazon : 1- 2 x 4 mg
se iha semana 3 – 4 kontrolo glicemia
seidauk adequadu,nia dose bele hasae
ba 1 – 2 x 8 mg
2.Pioglitazon : 1 x 15 – 30 mg
dose bele aumenta to 1 x 45 mg
Tiazolidinedionas (Glitazonas )
INIBIDORES DAS ALFAS GLICOSIDASES

- A indicação principal é o tratamento da hiper

glicemia pós-prandial, pois retarda a absorção
de carboidratos.
- Exemplo medikamento :
- Acarbose : 25 mg x 1 – 3 d.c
- Miglitol : 25 mg x 1 – 3 d.
INIBIDORES DAS ALFAS GLICOSIDASES
CREDITS: This presentation template was
created by Slidesgo, and includes icons by
Flaticon and infographics & images by Freepik

Hitler Mateus M
Departemento De Farmácia
FMCS - UNTL